Drug Pricing
Commentary
Medicare’s Drug Price Controls Could Actually Raise Prices In The Long Run
Four years ago, on August 16, President Biden signed the Inflation Reduction Act into law. Lawmakers promised that letting Medicare set drug prices would save taxpayers more than $100 billion over a decade. New research suggests the IRA may accomplish the opposite in the long run. A study by University ...
Commentary
CMS Undermining Next Generation of Medicines
Some of the biggest advances in medicine don’t come from discovering entirely new drugs. They come from making existing ones easier to take, faster to administer, safer, and more effective. A new proposal from the Centers for Medicare and Medicaid Services could make those improvements far less common. The agency ...
Commentary
Medicare’s Drug-Pricing Proposal Carries A Hidden Cost
The Trump administration says it wants to accelerate medical innovation. Yet one new proposal from the Centers for Medicare and Medicaid Services could do just the opposite. The agency has proposed a seemingly technical expansion of Medicare’s prescription drug price control scheme, which was created by the Inflation Reduction Act ...
Commentary
Medicare Pays Billions For Obesity’s Consequences. Its GLP-1 Bridge Offers A Better Way
Medicare spends billions of dollars each year treating heart disease, diabetes, kidney disease, cancer and other illnesses caused or worsened by obesity. Yet for decades, federal law has barred the program from covering medicines prescribed to treat obesity itself. In other words, Medicare has been willing to pay for the ...
Commentary
Approach online weight-loss drug offers with skepticism
If you’ve spent any time on social media lately, you’ve probably seen the ads. Lose weight fast. Get access to GLP-1s. Skip the doctor’s office. Delivered right to your door. For millions of Americans looking to lose weight, the promise is understandably appealing. These remarkable drugs, which include Ozempic, Wegovy, ...
Commentary
Don’t Blame Breakthrough Drugs for Costs, Fix Hospital Market
America’s healthcare tab has hit a new record. According to federal data published late last month, national health expenditures climbed to nearly $5.7 trillion in 2025, an increase of 7.3% over the previous year. The report noted that retail prescription drug spending rose 11%, driven in part by increased use ...
Biosimilars
PBM’s Drug Cut Exceeds the Total Cost of Medicines In Most Other Countries
Another fundamental problem is these comparisons rely on U.S. medicines’ gross (or list) price. But list prices do not account for the complex U.S. drug supply chain, where manufacturers receive only a portion of the gross price and intermediaries, such as pharmacy benefit managers (PBMs), receive a disproportionate share. As ...
Commentary
Congress should fulfill this drug program’s promise to vulnerable Californians
A federal program intended to help low-income patients has instead become a major revenue source for large California hospital systems. Hospitals are using gaps in oversight within the 340B Drug Pricing Program to lock in substantial margins on prescription drugs — and driving healthcare costs higher for Californians in the ...
Commentary
This Drug Patent Bill Would Hurt Innovation Without Lowering Prices
This week, the Senate Committee on Health, Education, Labor and Pensions will consider several bills that aim to “make health care more affordable and accessible to American families.” One in particular deserves a closer look. The Medication Affordability and Patent Integrity Act, introduced by Sen. Maggie Hassan, D-N.H., and co-sponsored ...
Commentary
Trump Should Stand Firm Against Europe’s Drug Price Free-Riders
For decades, wealthy foreign governments have left it to Americans to pay for pharmaceutical innovation — and then insisted on enjoying the fruits of that innovation at a discount. President Trump has begun challenging that status quo through trade negotiations designed to pressure foreign countries into paying more for innovative ...
Medicare’s Drug Price Controls Could Actually Raise Prices In The Long Run
Four years ago, on August 16, President Biden signed the Inflation Reduction Act into law. Lawmakers promised that letting Medicare set drug prices would save taxpayers more than $100 billion over a decade. New research suggests the IRA may accomplish the opposite in the long run. A study by University ...
CMS Undermining Next Generation of Medicines
Some of the biggest advances in medicine don’t come from discovering entirely new drugs. They come from making existing ones easier to take, faster to administer, safer, and more effective. A new proposal from the Centers for Medicare and Medicaid Services could make those improvements far less common. The agency ...
Medicare’s Drug-Pricing Proposal Carries A Hidden Cost
The Trump administration says it wants to accelerate medical innovation. Yet one new proposal from the Centers for Medicare and Medicaid Services could do just the opposite. The agency has proposed a seemingly technical expansion of Medicare’s prescription drug price control scheme, which was created by the Inflation Reduction Act ...
Medicare Pays Billions For Obesity’s Consequences. Its GLP-1 Bridge Offers A Better Way
Medicare spends billions of dollars each year treating heart disease, diabetes, kidney disease, cancer and other illnesses caused or worsened by obesity. Yet for decades, federal law has barred the program from covering medicines prescribed to treat obesity itself. In other words, Medicare has been willing to pay for the ...
Approach online weight-loss drug offers with skepticism
If you’ve spent any time on social media lately, you’ve probably seen the ads. Lose weight fast. Get access to GLP-1s. Skip the doctor’s office. Delivered right to your door. For millions of Americans looking to lose weight, the promise is understandably appealing. These remarkable drugs, which include Ozempic, Wegovy, ...
Don’t Blame Breakthrough Drugs for Costs, Fix Hospital Market
America’s healthcare tab has hit a new record. According to federal data published late last month, national health expenditures climbed to nearly $5.7 trillion in 2025, an increase of 7.3% over the previous year. The report noted that retail prescription drug spending rose 11%, driven in part by increased use ...
PBM’s Drug Cut Exceeds the Total Cost of Medicines In Most Other Countries
Another fundamental problem is these comparisons rely on U.S. medicines’ gross (or list) price. But list prices do not account for the complex U.S. drug supply chain, where manufacturers receive only a portion of the gross price and intermediaries, such as pharmacy benefit managers (PBMs), receive a disproportionate share. As ...
Congress should fulfill this drug program’s promise to vulnerable Californians
A federal program intended to help low-income patients has instead become a major revenue source for large California hospital systems. Hospitals are using gaps in oversight within the 340B Drug Pricing Program to lock in substantial margins on prescription drugs — and driving healthcare costs higher for Californians in the ...
This Drug Patent Bill Would Hurt Innovation Without Lowering Prices
This week, the Senate Committee on Health, Education, Labor and Pensions will consider several bills that aim to “make health care more affordable and accessible to American families.” One in particular deserves a closer look. The Medication Affordability and Patent Integrity Act, introduced by Sen. Maggie Hassan, D-N.H., and co-sponsored ...
Trump Should Stand Firm Against Europe’s Drug Price Free-Riders
For decades, wealthy foreign governments have left it to Americans to pay for pharmaceutical innovation — and then insisted on enjoying the fruits of that innovation at a discount. President Trump has begun challenging that status quo through trade negotiations designed to pressure foreign countries into paying more for innovative ...